Erratum: Evolution of oncolytic viruses: Novel strategies for cancer treatment (Immunotherapy (2013) 5:11 (1191-1206) DOI: 10.2217/imt.13.123);Evolution of oncolytic viruses: Novel strategies for cancer treatment

Immunotherapy

Volumn 5, Issue 11, 2013, Pages 1191-1206

  Atherton, Matthew J ^a   Lichty, Brian D ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

cancer; immunotherapy; oncolytic virus; tumor vaccine; virotherapy

Indexed keywords

CAVATAK; CGTG 102; G 207; GC0070; GL ONC1; HSV 1716; LONTUCIREV; MV CEA; MV NIS; NDV HUJ; ONCOLYTIC VIRUS; PARVORYX; PELAREOREP; PEXASTIMOGENE DEVACIREPVEC; PV 701; RAPAMYCIN; SUNITINIB; SVV 001; T VEC; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VALPROIC ACID; VSV IFN BETA;

ABSENCE OF SIDE EFFECTS; ADAPTIVE IMMUNITY; ADENOVIRUS; ANTINEOPLASTIC ACTIVITY; BLADDER CARCINOMA; CANCER CHEMOTHERAPY; CELL DEATH; COLORECTAL CARCINOMA; COXSACKIE VIRUS; DRUG EFFECT; DRUG TOLERABILITY; ENCEPHALITIS; EVOLUTION; FLU LIKE SYNDROME; GALLBLADDER CANCER; GLIOBLASTOMA; GLIOMA; HEAD AND NECK CANCER; HEALTH CARE QUALITY; HERPES SIMPLEX VIRUS; HUMAN; INFLUENZA VIRUS; LIVER CELL CARCINOMA; MEASLES VIRUS; MELANOMA; MELANOMA CELL; NEOPLASM; NEUROBLASTOMA; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; ONCOLYTIC VIROTHERAPY; OSTEOSARCOMA; OVARY CANCER; OVARY CARCINOMA; PANCREAS CARCINOMA; PARVOVIRUS; PERITONEUM CANCER; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; REOVIRUS; RETINOBLASTOMA; REVIEW; SOFT TISSUE SARCOMA; SOLID TUMOR; STOMACH CANCER; TRANSGENE; UTERINE TUBE CARCINOMA; VACCINIA VIRUS; VESICULAR STOMATITIS VIRUS; VIRUS REPLICATION;

ADAPTIVE IMMUNITY; ANIMALS; APOPTOSIS; AUTOPHAGY; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNITY, INNATE; NECROSIS; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES;

EID: 84887229566     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.14.52     Document Type: Erratum

References (178)

1. Dock G. The infuence of complicating diseases upon leukaemia. Am. J. Med. Sci. 127(4), 563-592 (1904).
2. Garber K. China approves world's frst oncolytic virus therapy for cancer treatment. J. Natl Cancer Inst. 98(5), 298-300 (2006).
3. Moore AE. The destructive effect of the virus of Russian far east encephalitis on the transplantable mouse sarcoma 180. Cancer 2(3), 525-534 (1949).
4. Pol JG, Resseguier J, Lichty BD. Oncolytic viruses: a step into cancer immunotherapy. Virus Adapt. Treat. 4, 1-21 (2011).
5. Everts B, van der Poel HG. Replication-selective oncolytic viruses in the treatment of cancer. Cancer Gene Ther. 12(2), 141-161 (2004).
6. Ramachandra M, Rahman A, Zou A et al. Re-engineering adenovirus regulatory pathways to enhance oncolytic specifcity and e f fc ac y. Nat. Biotechnol. 19(11), 1035-1041 (2001). (Pubitemid 33041887)
7. Kirn DH, Thorne SH. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat. Rev. Cancer 9(1), 64-71 (2009).
8. Bergmann M, Romirer I, Sachet M et al. A genetically engineered infuenza A virus with ras-dependent oncolytic properties. Cancer Res. 61(22), 8188-8193 (2001). (Pubitemid 33091611)
9. Gromeier M, Lachmann S, Rosenfeld MR, Gutin PH, Wimmer E. Intergeneric poliovirus recombinants for the treatment of malignant glioma. Proc. Natl Acad. Sci. USA 97(12), 6803-6808 (2000). (Pubitemid 30412795)
10. Varghese S, Rabkin SD. Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Ther. 9(12), 967-978 (2002). (Pubitemid 35462560)
11. Kruyt FAE, Curiel DT. Toward a new generation of conditionally replicating adenoviruses: pairing tumor selectivity with maximal oncolysis. Hum. Gene Ther. 13(4), 485-495 (2002). (Pubitemid 34253150)
12. Dmitriev I, Krasnykh V, Miller CR et al. An adenovirus vector with genetically modifed fbers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J. Virol. 72(12), 9706-9713 (1998). (Pubitemid 28520834)
13. Krasnykh V, Dmitriev I, Navarro J-G et al. Advanced generation adenoviral vectors possess augmented gene transfer effciency based upon coxsackie adenovirus receptor-independent cellular entry capacity. Cancer Res. 60(24), 6784-6787 (2000). (Pubitemid 32059138)
14. Mendelsohn CL, Wimmer E, Racaniello VR. Cellular receptor for poliovirus: molecular cloning, nucleotide sequence, and expression of a new member of the immunoglobulin superf am i ly. Cell 56(5), 855-865 (1989). (Pubitemid 19082521)
15. Merrill MK, Bernhardt G, Sampson JH, Wikstrand CJ, Bigner DD, Gromeier M. Poliovirus receptor CD155-targeted oncolysis of glioma. Neuro Oncol. 6(3), 208-217 (2004). (Pubitemid 39136504)
16. Gromeier M, Lachmann S, Rosenfeld MR, Gutin PH, Wimmer E. Intergeneric poliovirus recombinants for the treatment of malignant glioma. Proc. Natl Acad. Sci. USA 97(12), 6803-6808 (2000). (Pubitemid 30412795)
17. Sugiyama T, Yoneda M, Kuraishi T et al. Measles virus selectively blind to signaling lymphocyte activation molecule as a novel oncolytic virus for breast cancer treatment. Gene Ther. 20(3), 338-347 (2013).
18. Krishnamurthy S, Takimoto T, Scroggs RA, Portner A. Differentially regulated interferon response determines the outcome of newcastle disease virus infection in normal and tumor cell lines. J. Virol. 80 (11), 5145-5155 (2006).
19. Stojdl DF, Lichty B, Knowles S et al. Exploiting tumor-specifc defects in the interferon pathway with a previously unknown oncolytic virus. Nat. Med. 6(7), 821-825 (2000). (Pubitemid 30469434)
20. Stojdl DF, Lichty BD, tenOever BR et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 4(4), 263-275 (2003). (Pubitemid 37329791)
21. Muster T, Rajtarova J, Sachet M et al. Interferon resistance promotes oncolysis by infuenza virus NS1-deletion mutants. Int. J. Cancer 110(1), 15-21 (2004). (Pubitemid 38507199)
22. Van Rikxoort M, Michaelis M, Wolschek M et al. Oncolytic effects of a novel infuenza a virus expressing interleukin-15 from the NS reading frame. PLoS ONE 7(5), e36506 (2012).
23. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 144(5), 646-674 (2011).
24. Mansour M, Palese P, Zamarin D. Oncolytic specifcity of Newcastle disease virus is mediated by selectivity for apoptosis-resistant cells. J. Virol. 85(12), 6015-6023 (2011).
25. Guo ZS, Naik A, O'Malley ME et al. The enhanced tumor selectivity of an oncolytic Vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2. Cancer Res. 65(21), 9991-9998 (2005). (Pubitemid 41541480)
26. Wollmann G, Davis JN, Bosenberg MW, van den Pol AN. Vesicular stomatitis virus variants selectively infect and kill human melanomas but not normal melanocytes. J. Virol. 87(12), 6644-6659 (2013).
27. Rommelaere J, Geletneky K, Angelova AL et al. Oncolytic parvoviruses as cancer therapeutics. Cytokine Growth Factor Rev. 21(2), 185-195 (2010).
28. Norman KL, Hirasawa K, Yang AD, Shields MA, Lee PW. Reovirus oncolysis: the Ras/RalGEF/p38 pathway dictates host cell permissiveness to reovirus infection. Proc. Natl Acad. Sci. USA. 101(30), 11099-11104 (2004). (Pubitemid 38989590)
29. Alegre MM, Robison RA, O'Neill KL. Thymidine kinase 1 upregulation is an early event in breast tumor formation. J. Oncol. 2012, 575647 (2012).
30. Puhlmann M, Brown CK, Gnant M et al. Vaccinia as a vector for tumor-directed gene therapy: biodistribution of a thymidine kinase-deleted mutant. Cancer Gene Ther. 7(1), 66-73 (2000) (Pubitemid 30080989)
31. Shobana R, Samal SK, Elankumaran S. Prostate-specifc antigen-retargeted recombinant newcastle disease virus for prostate cancer virotherapy. J. Virol. 87(7), 3792-3800 (2013).
32. Chu RL, Post DE, Khuri FR, Meir EGV. Use of replicating oncolytic adenoviruses in combination therapy for cancer. Clin. Cancer Res. 10(16), 5299-5312 (2004). (Pubitemid 39100464)
33. Todo T. "Armed" oncolytic herpes simplex viruses for brain tumor therapy. Cell Adhes. Migr. 2(3), 208-213 (2008).
34. White E. Regulation of apoptosis by adenovirus E1A and E1B oncogenes. Semin. Virol. 8(6), 505-513 (1998). (Pubitemid 28438489)
35. Bischoff JR, Kirn DH, Williams A et al. An adenovirus mutant that replicates selectively in p53-defcient human tumor cells. Science. 274(5286), 373-376 (1996). (Pubitemid 26353341)
36. Nevins JR. The Rb/E2F pathway and cancer. Hum. Mol. Genet. 10(7), 699-703 (2001). (Pubitemid 32331578)
37. Heise C, Hermiston T, Johnson L et al. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral effcacy. Nat. Med. 6(10), 1134-1139 (2000).
38. Fukuda K, Abei M, Ugai H et al. E1A, E1B double-restricted adenovirus for oncolytic gene therapy of gallbladder cancer. Cancer Res. 63(15), 4434-4440 (2003). (Pubitemid 36951015)
39. Tollefson AE, Ryerse JS, Scaria A, Hermiston TW, Wold WS. The E3-11.6-kDa adenovirus death protein (ADP) is required for effcient cell death: characterization of cells infected with adp mutants. Virology 220(1), 152-162 (1996). (Pubitemid 26201673)
40. Shtrichman R, Kleinberger T. Adenovirus type 5 E4 open reading frame 4 protein induces apoptosis in transformed cells. J. Virol. 72(4), 2975-2982 (1998). (Pubitemid 28175536)
41. Ebert O, Shinozaki K, Kournioti C, Park MS, García-Sastre A, Woo SL. Syncytia induction enhances the oncolytic potential of vesicular stomatitis virus in virotherapy for cancer. Cancer Res. 64(9), 3265-3270 (2004). (Pubitemid 38581431)
42. Wohlfahrt ME, Beard BC, Lieber A, Kiem HP. A capsid-modifed, conditionally replicating oncolytic adenovirus vector expressing TRAIL leads to enhanced cancer cell killing in human glioblastoma models. Cancer Res. 67(18), 8783-8790 (2007). (Pubitemid 47437454)
43. Zhu W, Wei L, Zhang H, Chen J, Qin X. Oncolytic adenovirus armed with IL-24 Inhibits the growth of breast cancer in vitro and in vivo. J. Exp. Clin. Cancer Res. 31(1), 51 (2012).
44. Tamura K, Wakimoto H, Agarwal AS et al. Multimechanistic tumor targeted oncolytic virus overcomes resistance in brain tumors. Mol. Ther. 21(1), 68-77 (2013).
45. Shen W, Wang CY, Wang XH, Fu ZX. Oncolytic adenovirus mediated Survivin knockdown by RNA interference suppresses human colorectal carcinoma growth in vitro and in vivo. J. Exp. Clin. Cancer Res. 28(1), 81 (2009).
46. Zheng JN, Pei DS, Sun FH et al. Inhibition of renal cancer cell growth by oncolytic adenovirus armed short hairpin RNA targeting hTERT gene. Cancer Biol. Ther. 8(1), 84-91 (2009).
47. Zheng JN, Pei DS, Mao LJ et al. Inhibition of renal cancer cell growth in vitro and in vivo with oncolytic adenovirus armed short hairpin RNA targeting Ki-67 encoding mRNA. Cancer Gene Ther. 16(1), 20-32 (2008).
48. van Beusechem VW, van den Doel PB, Grill J, Pinedo HM, Gerritsen WR. Conditionally replicative adenovirus expressing p53 exhibits enhanced oncolytic potency. Cancer Res. 62(21), 6165-6171 (2002). (Pubitemid 35244467)
49. Ma J, Ma J, He X et al. E2F promoter-regulated oncolytic adenovirus with p16 gene induces cell apoptosis and exerts antitumor effect on gastric cancer. Dig. Dis. Sci. 54(7), 1425-1431 (2009).
50. Jiang H, Gomez-Manzano C, Aoki H et al. Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death. J. Natl Cancer Inst. 99(18), 1410-1414 (2007). (Pubitemid 351767180)
51. Breitbach CJ, De Silva NS, Falls TJ et al. Targeting tumor vasculature with an oncolytic virus. Mol. Ther. 19(5), 886-894 (2011).
52. Breitbach CJ, Arulanandam R, Silva ND et al. Oncolytic Vaccinia virus disrupts tumor-associated vasculature in humans. Cancer Res. 73(4), 1265-1275 (2013).
53. Prestwich RJ, Errington F, Diaz RM et al. The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon. Hum. Gene Ther. 20(10), 1119-1132 (2009).
54. Zhu J, Martinez J, Huang X, Yang Y. Innate immunity against Vaccinia virus is mediated by TLR2 and requires TLR-independent production of IFN-b. Blood. 109(2), 619-625 (2007). (Pubitemid 46105962)
55. Endo Y, Sakai R, Ouchi M et al. Virus-mediated oncolysis induces danger signal and stimulates cytotoxic T-lymphocyte activity via proteasome activator upregulation. Oncogene 27(17), 2375-2381 (2007). (Pubitemid 351521091)
56. Bai L, Koopmann J, Fiola C, Fournier P, Schirrmacher V. Dendritic cells pulsed with viral oncolysates potently stimulate autologous T cells from cancer patients. Int. J. Oncol. 21(4), 685-694 (2002).
57. Gauvrit A, Brandler S, Sapede-Peroz C, Boisgerault N, Tangy F, Gregoire M. Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specifc CD8 response. Cancer Res. 68(12), 4882-4892 (2008).
58. Rommelfanger DM, Grau MC, Diaz RM et al. The effcacy versus toxicity profle of combination virotherapy and TLR immunotherapy highlights the danger of administering tlr agonists to oncolytic virus-treated mice. Mol. Ther. 21(2), 348-357 (2013).
59. Benencia F, Courrèges MC, Conejo-García JR et al. HSV oncolytic therapy upregulates interferon-inducible chemokines and recruits immune effector cells in ovarian cancer. Mol. Ther. 12(5), 789-802 (2005). (Pubitemid 41614474)
60. Miller CG, Fraser NW. Role of the immune response during neuro-attenuated herpes simplex virus-mediated tumor destruction in a murine intracranial melanoma model. Cancer Res. 60(20), 5714-5722 (2000).
61. Moehler MH, Zeidler M, Wilsberg V et al. Parvovirus H-1-induced tumor cell death enhances human immune response in vitro via increased phagocytosis, maturation, and cross-presentation by dendritic cells. Hum. Gene Ther. 16(8), 996-1005 (2005). (Pubitemid 41153868)
62. Errington F, White CL, Twigger KR et al. Infammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma. Gene Ther. 15(18), 1257-1270 (2008).
63. Steele L, Errington F, Prestwich R et al. Pro-infammatory cytokine/chemokine production by reovirus treated melanoma cells is PKR/NF-kB mediated and supports innate and adaptive anti-tumour immune priming. Mol. Cancer 10(1), 20 (2011).
64. Gujar SA, Marcato P, Pan D, Lee PW. Reovirus virotherapy overrides tumor antigen presentation evasion and promotes protective antitumor immunity. Mol. Cancer Ther. 9(11), 2924-2933 (2010).
65. Prestwich RJ, Errington F, Ilett EJ et al. Tumor infection by oncolytic reovirus primes adaptive antitumor immunity. Clin. Cancer Res. 14(22), 7358-7366 (2008).
66. Diaz RM, Galivo F, Kottke T et al. Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus. Cancer Res. 67(6), 2840-2848 (2007). (Pubitemid 46548974)
67. Prestwich RJ, Ilett EJ, Errington F et al. Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication. Clin. Cancer Res. 15(13), 4374-4381 (2009).
68. Markert JM, Medlock MD, Rabkin SD et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a Phase I trial. Gene Ther. 7(10), 867-874 (2000). (Pubitemid 30303584)
69. Rampling R, Cruickshank G, Papanastassiou V et al. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther. 7(10), 859-866 (2000). (Pubitemid 30303583)
70. Ganly I, Kirn D, Eckhardt SG et al. A Phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin. Cancer Res. 6(3), 798-806 (2000). (Pubitemid 30159332)
71. Pesonen S, Kangasniemi L, Hemminki A. Oncolytic adenoviruses for the treatment of human cancer: focus on translational and clinical data. Mol. Pharm. 8(1), 12-28 (2011).
72. Pecora AL, Rizvi N, Cohen GI et al. Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J. Clin. Oncol. 20(9), 2251-2266 (2002). (Pubitemid 34441652)
73. Galanis E, Hartmann LC, Cliby WA et al. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res. 70(3), 875-882 (2010).
74. Ausubel LJ, Meseck M, Derecho I et al. Current good manufacturing practice production of an oncolytic recombinant vesicular stomatitis viral vector for cancer treatment. Hum. Gene Ther. 22(4), 489-497 (2011).
75. Breitbach CJ, Burke J, Jonker D et al. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 477(7362), 99-102 (2011).
76. Heo J, Reid T, Ruo L et al. Randomized dose-fnding clinical trial of oncolytic immunotherapeutic Vaccinia JX-594 in liver cancer. Nat. Med. 19(3), 329-336 (2013).
77. ® (reovirus serotype-3-dearing strain) in patients with metastatic melanoma. Mol. Ther. 20(10), 1998-2003 (2012).
78. Senzer NN, Kaufman HL, Amatruda T et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J. Clin. Oncol. 27(34), 5763-5771 (2009).
79. Kaufman HL, Bines SD. OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma. Future Oncol. 6(6), 941-949 (2010).
80. Ingemar Andtbacka RH, Collichio FA et al. OPTiM: a randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma. J. Clin. Oncol. 31(Suppl.), Abstract LBA9008 (2013).
81. Hummel JL, Safroneeva E, Mossman KL. The role of ICP0-null HSV-1 and interferon signaling defects in the effective treatment of breast adenocarcinoma. Mol. Ther. 12(6), 1101-1110 (2005). (Pubitemid 41723044)
82. Liu BL, Robinson M, Han Z-Q et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther. 10(4), 292-303 (2003). (Pubitemid 36305598)
83. Lemay CG, Rintoul JL, Kus A et al. Harnessing oncolytic virus-mediated antitumor immunity in an infected cell vaccine. Mol. Ther. 20(9), 1791-1799 (2012).
84. Cerullo V, Diaconu I, Romano V et al. An oncolytic adenovirus enhanced for toll-like receptor 9 stimulation increases antitumor immune responses and tumor clearance. Mol. Ther. 20(11), 2076-2086 (2012).
85. + T Cells after intratumoral Ad5-TRAIL/CpG oligodeoxynucleotide combination therapy. Cancer Res. 67(24), 11980-11990 (2007).
86. Raykov Z, Grekova S, Leuchs B, Aprahamian M, Rommelaere J. Arming parvoviruses with CpG motifs to improve their oncosuppressive cap a cit y. Int. J. Cancer. 122(12), 2880-2884 (2008). (Pubitemid 351631394)
87. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat. Rev. Cancer. 4(1), 11-22 (2004). (Pubitemid 38111131)
88. Homey B, Müller A, Zlotnik A. Chemokines: agents for the immunotherapy of cancer? Nat. Rev. Immunol. 2(3), 175-184 (2002). (Pubitemid 37328764)
89. Lee S, Margolin K. Cytokines in Cancer Immunotherapy. Cancers 3(4), 3856-3893 (2011).
90. Chen H, Sampath P, Hou W, Thorne SH. Regulating cytokine function enhances safety and activity of genetic cancer therapies. Mol. Ther. 21(1), 167-174 (2013).
91. Hu JC, Coffn RS, Davis CJ et al. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin. Cancer Res. 12(22), 6737-6747 (2006). (Pubitemid 44876843)
92. Harrington KJ, Hingorani M, Tanay MA et al. Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck. Clin. Cancer Res. 16 (15), 4005-4015 (2010).
93. Kaufman HL, Kim DW, DeRaffele G, Mitcham J, Coffn RS, Kim-Schulze S. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann. Surg. Oncol. 17(3), 718-730 (2010).
94. Park BH, Hwang T, Liu TC et al. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a Phase I trial. Lancet Oncol. 9(6), 533-542 (2008).
95. Kim JH, Oh JY, Park BH et al. Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. Mol. Ther. 14(3), 361-370 (2006). (Pubitemid 44184970)
96. Lee JH, Roh MS, Lee YK et al. Oncolytic and immunostimulatory effcacy of a targeted oncolytic poxvirus expressing human GM-CSF following intravenous administration in a rabbit tumor model. Cancer Gene Ther. 17(2), 73-79 (2010).
97. Chang J, Zhao X, Wu X et al. A Phase I study of KH901, a conditionally replicating granulocyte-macrophage colony-stimulating factor: armed oncolytic adenovirus for the treatment of head and neck cancers. Cancer Biol. Ther. 8(8), 676-682 (2009).
98. Cerullo V, Pesonen S, Diaconu I et al. Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients. Cancer Res. 70(11), 4297-4309 (2010).
99. Lei N, Shen FB, Chang JH et al. An oncolytic adenovirus expressing granulocyte macrophage colony-stimulating factor shows improved specifcity and effcacy for treating human solid tumors. Cancer Gene Ther. 16(1), 33-43 (2008).
100. Vigil A, Park MS, Martinez O et al. Use of reverse genetics to enhance the oncolytic properties of newcastle disease virus. Cancer Res. 67(17), 8285-8292 (2007). (Pubitemid 47395166)
101. Janke M, Peeters B, de Leeuw O et al. Recombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy. Gene Ther. 14(23), 1639-1649 (2007). (Pubitemid 350143189)
102. Bergman I, Griffn JA, Gao Y, Whitaker-Dowling P. Treatment of implanted mammary tumors with recombinant vesicular stomatitis virus targeted to Her2/neu. Int. J. Cancer 121(2), 425-430 (2007). (Pubitemid 46917713)
103. Grote D, Cattaneo R, Fielding AK. Neutrophils contribute to the measles virus-induced antitumor effect: enhancement by granulocyte macrophage colony-stimulating factor expression. Cancer Res. 63(19), 6463-6468 (2003). (Pubitemid 37255198)
104. Braun SE, Chen K, Blazar BR et al. Flt3 ligand antitumor activity in a murine breast cancer model: a comparison with granulocyte-macrophage colony-stimulating factor and a potential mechanism of action. Hum. Gene Ther. 10(13), 2141-2151 (1999). (Pubitemid 29416294)
105. McKenna HJ. Role of hematopoietic growth factors/ft3 ligand in expansion and regulation of dendritic cells. Curr. Opin. Hematol. 8(3), 149-154 (2001). (Pubitemid 32324635)
106. Bernt KM, Ni S, Tieu AT, Lieber A. Assessment of a combined, adenovirus-mediated oncolytic and immunostimulatory tumor therapy. Cancer Res. 65(10), 4343-4352 (2005). (Pubitemid 40775673)
107. Ramakrishna E, Woller N, Mundt B et al. Antitumoral immune response by recruitment and expansion of dendritic cells in tumors infected with telomerase-dependent oncolytic viruses. Cancer Res. 69(4), 1448-1458 (2009).
108. Barnard Z, Wakimoto H, Zaupa C et al. Expression of FMS-like tyrosine kinase 3 ligand by oncolytic herpes simplex virus type I prolongs survival in mice bearing established syngeneic intracranial malignant glioma. Neurosurgery 71(3), 741-748; discussion 748 (2012).
109. Dieu MC, Vanbervliet B, Vicari A et al. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J. Exp. Med. 188(2), 373-386 (1998). (Pubitemid 28357765)
110. Li J, O'Malley M, Urban J et al. Chemokine expression from oncolytic Vaccinia virus enhances vaccine therapies of cancer. Mol. Ther. 19(4), 650-657 (2011).
111. Lapteva N, Aldrich M, Weksberg D et al. Targeting the intratumoral dendritic cells by the oncolytic adenoviral vaccine expressing RANTES elicits potent antitumor immunity. J. Immunother. 32(2), 145-156 (2009).
112. Li J, Liu H, Li L et al. The combination of an oxygen-dependent degradation domain-regulated adenovirus expressing the chemokine RANTES/CCL5 and NK-92 cells exerts enhanced antitumor activity in hepatocellular carcinoma. Oncol. Rep. 29(3), 895-902 (2013).
113. Smyth MJ, Cretney E, Kershaw MH, Hayakawa Y. Cytokines in cancer immunity and immunotherapy. Immunol. Rev. 202(1), 275-293 (2004). (Pubitemid 39576919)
114. Carew JF, Kooby DA, Halterman MW, Kim SH, Federoff HJ, Fong Y. A novel approach to cancer therapy using an oncolytic herpes virus to package amplicons containing cytokine genes. Mol. Ther. 4(3), 250-256 (2001). (Pubitemid 32851289)
115. Zhao H, Janke M, Fournier P, Schirrmacher V. Recombinant Newcastle disease virus expressing human interleukin-2 serves as a potential candidate for tumor therapy. Virus Res. 136(1-2), 75-80 (2008).
116. Portielje JE, Gratama J, Ojik HH van, Stoter G, Kruit WH. IL-12: a promising adjuvant for cancer vaccination. Cancer Immunol. Immunother. 52(3), 133-144 (2003). (Pubitemid 36384713)
117. Choi IK, Lee JS, Zhang SN et al. Oncolytic adenovirus co-expressing IL-12 and IL-18 improves tumor-specifc immunity via differentiation of T cells expressing IL-12Rb2 or IL-18Ra. Gene Ther. 18(9), 898-909 (2011).
118. Varghese S, Rabkin SD, Liu R, Nielsen PG, Ipe T, Martuza RL. Enhanced therapeutic effcacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers. Cancer Gene Ther. 13(3), 253-265 (2006). (Pubitemid 43255762)
119. Derubertis BG, Stiles BM, Bhargava A et al. Cytokine-secreting herpes viral mutants effectively treat tumor in a murine metastatic colorectal liver model by oncolytic and T-cell-dependent mechanisms. Cancer Gene Ther. 14(6), 590-597 (2007). (Pubitemid 46788334)
120. Shin EJ, Wanna GB, Choi B et al. Interleukin-12 expression enhances vesicular stomatitis virus oncolytic therapy in murine squamous cell carcinoma. Laryngoscope 117(2), 210-214 (2007). (Pubitemid 46207874)
121. Cody JJ, Scaturro P, Cantor AB, Yancey Gillespie G, Parker JN, Markert JM. Preclinical evaluation of oncolytic herpes simplex virus expressing interleukin-12 for therapy of breast cancer brain metastases. Int. J. Breast Cancer 2012, 628697 (2012).
122. Wong RJ, Chan MK, Yu Z et al. Angiogenesis inhibition by an oncolytic herpes virus expressing interleukin 12. Clin. Cancer Res. 10(13), 4509-4516 (2004) (Pubitemid 38878895)
123. Zhang W, Fulci G, Wakimoto H et al. Combination of oncolytic herpes simplex viruses armed with angiostatin and IL-12 enhances antitumor effcacy in human glioblastoma models. Neoplasia 15 (6), 591-599 (2013).
124. Shashkova EV, Kuppuswamy MN, Wold WSM, Doronin K. Anticancer activity of oncolytic adenovirus vector armed with IFN-alpha and ADP is enhanced by pharmacologically controlled expression of TRAIL. Cancer Gene Ther. 15(2), 61-72 (2008).
125. Shashkova EV, Spencer JF, Wold WSM, Doronin K. Targeting interferon-alpha increases antitumor effcacy and reduces hepatotoxicity of E1A-mutated spread-enhanced oncolytic adenovirus. Mol. Ther. 15(3), 598-607 (2007).
126. Han ZQ, Assenberg M, Liu BL et al. Development of a second-generation oncolytic Herpes simplex virus expressing TNF alpha for cancer therapy. J. Gene Med. 9(2), 99-106 (2007). (Pubitemid 46444487)
127. Stephenson KB, Barra NG, Davies E, Ashkar AA, Lichty BD. Expressing human interleukin-15 from oncolytic vesicular stomatitis virus improves survival in a murine metastatic colon adenocarcinoma model through the enhancement of anti-tumor immunity. Cancer Gene Ther. 19(4), 238-246 (2012).
128. Kim HS, Kim-Schulze S, Kim DW, Kaufman HL. Host lymphodepletion enhances the therapeutic activity of an oncolytic Vaccinia virus expressing 4-1BB ligand. Cancer Res. 69(21), 8516-8525 (2009).
129. Huang JH, Zhang SN, Choi KJ et al. Therapeutic and tumor-specifc immunity induced by combination of dendritic cells and oncolytic adenovirus expressing IL-12 and 4-1BBL. Mol. Ther. 18(2), 264-274 (2010).
130. Gomes EM, Rodrigues MS, Phadke AP et al. Antitumor activity of an oncolytic adenoviral-CD40 Ligand (CD154) transgene construct in human breast cancer cells. Clin. Cancer Res. 15(4), 1317-1325 (2009).
131. Galivo F, Diaz RM, Thanarajasingam U et al. Interference of CD40L-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus. Hum. Gene Ther. 21(4), 439-450 (2010).
132. Todo T, Martuza RL, Dallman MJ, Rabkin SD. In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity. Cancer Res. 61(1), 153-161 (2001). (Pubitemid 32095713)
133. Choi KJ, Kim JH, Lee YS et al. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect. Gene Ther. 13(13), 1010-1020 (2006).
134. Lee YS, Kim JH, Choi KJ et al. Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7-1 in an immunocompetent murine model. Clin. Cancer Res. 12(19), 5859-5868 (2006).
135. Fukuhara H, Ino Y, Kuroda T, Martuza RL, Todo T. Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artifcial chromosome-mediated system. Cancer Res. 65(23), 10663-10668 (2005). (Pubitemid 41713331)
136. Ino Y, Saeki Y, Fukuhara H, Todo T. Triple combination of oncolytic herpes simplex virus-1 vectors armed with interleukin-12, interleukin-18, or soluble B7-1 results in enhanced antitumor effcacy. Clin. Cancer Res. 12(2), 643-652 (2006). (Pubitemid 43166160)
137. Haen SP, Rammensee H-G. The repertoire of human tumor-associated epitopes-identifcation and selection of antigens and their application in clinical trials. Curr. Opin. Immunol. 25(2), 277-283 (2013).
138. Chuang CM, Monie A, Wu A, Pai SI, Hung CF. Combination of viral oncolysis and tumor-specifc immunity to control established tumors. Clin. Cancer Res. 15(14), 4581-4588 (2009).
139. Vigil A, Martinez O, Chua MA, García-Sastre A. Recombinant Newcastle disease virus as a vaccine vector for cancer therapy. Mol. Ther. 16(11), 1883-1890 (2008).
140. Bridle BW, Stephenson KB, Boudreau JE et al. Potentiating cancer immunotherapy using an oncolytic virus. Mol. Ther. 18(8), 1430-1439 (2010).
141. Wongthida P, Diaz RM, Pulido C et al. Activating systemic T-cell immunity against self tumor antigens to support oncolytic virotherapy with vesicular stomatitis virus. Hum. Gene Ther. 22(11), 1343-1353 (2011).
142. Harrop R, John J, Carroll MW. Recombinant viral vectors: cancer vaccines. Adv. Drug Deliv. Rev. 58(8), 931-947 (2006). (Pubitemid 44709263)
143. Elzey BD, Siemens DR, Ratliff TL, Lubaroff DM. Immunization with type 5 adenovirus recombinant for a tumor antigen in combination with recombinant canarypox virus (ALVAC) cytokine gene delivery induces destruction of established prostate tumors. Int. J. Cancer. 94(6), 842-849 (2001). (Pubitemid 33032833)
144. Näslund TI, Uyttenhove C, Nordström EKL et al. Comparative prime-boost vaccinations using Semliki Forest virus, adenovirus, and ALVAC vectors demonstrate differences in the generation of a protective central memory CTL response against the P815 tumor. J. Immunol. Baltim. 178(11), 6761-6769 (2007). (Pubitemid 46847400)
145. Hodge JW, Poole DJ, Aarts WM, Gómez Yafal A, Gritz L, Schlom J. Modifed Vaccinia virus ankara recombinants are as potent as Vaccinia recombinants in diversifed prime and boost vaccine regimens to elicit therapeutic antitumor responses. Cancer Res. 63(22), 7942-7949 (2003). (Pubitemid 37466731)
146. Buonaguro L, Petrizzo A, Tornesello ML, Buonaguro FM. Translating tumor antigens into cancer vaccines. Clin. Vaccine Immunol. 18(1), 23-34 (2011).
147. Pulido J, Kottke T, Thompson J et al. Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma. Nat. Biotechnol. 30(4), 337-343 (2012).
148. Brun J, McManus D, Lefebvre C et al. Identifcation of genetically modifed Maraba virus as an oncolytic rhabdovirus. Mol. Ther. 18(8), 1440-1449 (2010).
149. Qiao J, Wang H, Kottke T et al. Loading of oncolytic vesicular stomatitis virus onto antigen-specifc T cells enhances the effcacy of adoptive T-cell therapy of tumors. Gene Ther. 15(8), 604-616 (2008).
150. Kanzaki A, Kasuya H, Yamamura K et al. Antitumor effcacy of oncolytic herpes simplex virus adsorbed onto antigen-specifc lymphocytes. Cancer Gene Ther. 19(4), 292-298 (2012).
151. Rommelfanger DM, Wongthida P, Diaz RM et al. Systemic combination virotherapy for melanoma with tumor antigen-expressing vesicular stomatitis virus and adoptive T-cell transfer. Cancer Res. 72(18), 4753-4764 (2012).
152. + T cell recall responses. Blood 121(13), 2432-2439 (2013).
153. Boudreau JE, Bridle BW, Stephenson KB et al. Recombinant vesicular stomatitis virus transduction of dendritic cells enhances their ability to prime innate and adaptive antitumor immunity. Mol. Ther. 17(8), 1465-1472 (2009).
154. John LB, Howland LJ, Flynn JK et al. Oncolytic virus and anti-4-1BB combination therapy elicits strong antitumor immunity against established cancer. Cancer Res. 72(7), 1651-1660 (2012).
155. Kambara H, Saeki Y, Chiocca EA. Cyclophosphamide allows for in vivo dose reduction of a potent oncolytic virus. Cancer Res. 65(24), 11255-11258 (2005). (Pubitemid 41821678)
156. Fulci G, Breymann L, Gianni D et al. Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc. Natl Acad. Sci. USA 103(34), 12873-12878 (2006). (Pubitemid 44298654)
157. Kanai R, Rabkin SD, Yip S et al. Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells. J. Natl Cancer Inst. 104(1), 42-55 (2012).
158. Fujiwara T, Kagawa S, Kishimoto H et al. Enhanced antitumor effcacy of telomerase-selective oncolytic adenoviral agent OBP-401 with docetaxel: preclinical evaluation of chemovirotherapy. Int. J. Cancer 119(2), 432-440 (2006).
159. Lin SF, Gao SP, Price DL et al. Synergy of a Herpes oncolytic virus and paclitaxel for anaplastic thyroid cancer. Clin. Cancer Res. 14 (5), 1519-1528 (2008). (Pubitemid 351413937)
160. Chahlavi A, Todo T, Martuza RL, Rabkin SD. Replication-competent herpes simplex virus vector g207 and cisplatin combination therapy for head and neck squamous cell carcinoma. Neoplasia 1(2), 162-169 (1999).
161. Li Y, Yu DC, Chen Y et al. A hepatocellular carcinoma-specifc adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin. Cancer Res. 61(17), 6428-6436 (2001). (Pubitemid 32783248)
162. Cinatl J Jr, Cinatl J, Michaelis M et al. Potent oncolytic activity of multimutated herpes simplex virus G207 in combination with vincristine against human rhabdomyosarcoma. Cancer Res. 63(7), 1508-1514 (2003). (Pubitemid 36373636)
163. Passer BJ, Cheema T, Wu S, Wu CL, Rabkin SD, Martuza RL. Combination of vinblastine and oncolytic herpes simplex virus vector expressing IL-12 therapy increases antitumor and antiangiogenic effects in prostate cancer models. Cancer Gene Ther. 20(1), 17-24 (2013).
164. Kaufmann JK, Bossow S, Grossardt C et al. Chemovirotherapy of malignant melanoma with a targeted and armed oncolytic measles virus. J. Invest. Dermatol. 133(4), 1034-1042 (2013).
165. Ververis K, Hiong A, Karagiannis TC, Licciardi PV. Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents. Biol. Targets Ther. 7, 47-60 (2013).
166. White MC, Frampton AR. The histone deacetylase inhibitor valproic acid enhances equine herpesvirus type 1 (EHV-1)-mediated oncolysis of human glioma cells. Cancer Gene Ther. 20(2), 88-93 (2013).
167. Bridle BW, Chen L, Lemay CG et al. HDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapy. Mol. Ther. 21(4), 887-894 (2013).
168. Alvarez-Breckenridge CA, Yu J, Price R et al. The histone deacetylase inhibitor valproic acid lessens NK cell action against oncolytic virus-infected glioblastoma cells by inhibition of STAT5/T-BET signaling and generation of gamma interferon. J. Virol. 86(8), 4566-4577 (2012).
169. Fu X, Tao L, Rivera A, Zhang X. Rapamycin enhances the activity of oncolytic herpes simplex virus against tumor cells that are resistant to virus replication. Int. J. Cancer. 129(6), 1503-1510 (2011).
170. Jha BK, Dong B, Nguyen CT, Polyakova I, Silverman RH. Suppression of antiviral innate immunity by sunitinib enhances oncolytic virotherapy. Mol. Ther. 21(9), 1749-1757 (2013).
171. Touchefeu Y, Vassaux G, Harrington KJ. Oncolytic viruses in radiation oncology. Radiother. Oncol. 99(3), 262-270 (2011).
172. Hallahan DE, Mauceri HJ, Seung LP et al. Spatial and temporal control of gene therapy using ionizing radiation. Nat. Med. 1(8), 786-791 (1995).
173. Buckel L, Advani SJ, Frentzen A et al. Combination of fractionated irradiation with anti-VEGF expressing Vaccinia virus therapy enhances tumor control by simultaneous radiosensitization of tumor associated endothelium. Int. J. Cancer (2013).
174. Muthana M, Rodrigues S, Chen Y-Y et al. Macrophage delivery of an oncolytic virus abolishes tumor regrowth and metastasis after chemotherapy or irradiation. Cancer Res. 73(2), 490-495 (2013).
175. Harrington KJ, Melcher A, Vassaux G, Pandha HS, Vile RG. Exploiting synergies between radiation and oncolytic viruses. Curr. Opin. Mol. Ther. 10(4), 362-370 (2008).
176. Ferguson MS, Lemoine NR, Wang Y. Systemic delivery of oncolytic viruses: hopes and hurdles. Adv. Virol. 2012, 805629 (2012).
177. Tesfay MZ, Kirk AC, Hadac EM et al. PEGylation of vesicular stomatitis virus extends virus persistence in blood circulation of passively immunized mice. J. Virol. 87(7), 3752-3759 (2013).
178. Cheema TA, Wakimoto H, Fecci PE et al. Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model. Proc. Natl Acad. Sci. 110 (29), 12006-12011 (2013).